Geron (GERN) Scheduled to Post Quarterly Earnings on Thursday

Geron (NASDAQ:GERN - Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Geron to post earnings of ($0.08) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). The firm had revenue of $0.88 million for the quarter, compared to the consensus estimate of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. During the same quarter last year, the business posted ($0.09) earnings per share. The firm's revenue was up 2941.4% compared to the same quarter last year. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Trading Down 1.0 %

Shares of GERN traded down $0.04 during midday trading on Thursday, reaching $4.11. The company had a trading volume of 4,651,084 shares, compared to its average volume of 10,358,183. Geron has a 1-year low of $1.64 and a 1-year high of $5.34. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12. The firm has a 50 day simple moving average of $4.36 and a 200-day simple moving average of $4.28. The stock has a market cap of $2.48 billion, a PE ratio of -11.42 and a beta of 0.50.

Analysts Set New Price Targets

Several research firms recently issued reports on GERN. Scotiabank began coverage on shares of Geron in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $6.00 price objective for the company. Leerink Partnrs raised shares of Geron to a "strong-buy" rating in a research report on Monday, September 9th. StockNews.com upgraded Geron to a "sell" rating in a research report on Monday, August 5th. Leerink Partners assumed coverage on Geron in a research note on Monday, September 9th. They set an "outperform" rating and a $7.00 target price for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 price target on shares of Geron in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Geron currently has an average rating of "Moderate Buy" and a consensus price target of $6.94.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.